➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Boehringer Ingelheim
Dow
McKesson
Johnson and Johnson
AstraZeneca

Last Updated: May 30, 2020

DrugPatentWatch Database Preview

Biologic Drugs With Mechanism of Action: CD30-directed Antibody Interactions


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Biologic Drugs With Mechanism of Action: CD30-directed Antibody Interactions

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Seattle Genetics ADCETRIS brentuximab vedotin INJECTABLE; INJECTION 125388 001 2011-08-19   Start Trial University of Georgia Research Foundation, Inc. (Athens, GA) 2039-02-26 RX Orphan search
Seattle Genetics ADCETRIS brentuximab vedotin INJECTABLE; INJECTION 125388 001 2011-08-19   Start Trial SUNSHINE LAKE PHARMA CO., LTD. (Dongguan, Guangdong, CN) 2034-07-17 RX Orphan search
Seattle Genetics ADCETRIS brentuximab vedotin INJECTABLE; INJECTION 125388 001 2011-08-19   Start Trial CureVac AG (Tubingen, DE) 2032-02-15 RX Orphan search
Seattle Genetics ADCETRIS brentuximab vedotin INJECTABLE; INJECTION 125388 001 2011-08-19   Start Trial Celgene Corporation (Summit, NJ) 2035-12-02 RX Orphan search
Seattle Genetics ADCETRIS brentuximab vedotin INJECTABLE; INJECTION 125388 001 2011-08-19   Start Trial SEATTLE GENETICS, INC. (Bothell, WA) 2030-10-22 RX Orphan search
Seattle Genetics ADCETRIS brentuximab vedotin INJECTABLE; INJECTION 125388 001 2011-08-19   Start Trial ALX ONCOLOGY INC. (Burlingame, CA) 2035-08-07 RX Orphan search
Seattle Genetics ADCETRIS brentuximab vedotin INJECTABLE; INJECTION 125388 001 2011-08-19   Start Trial CytomX Therapeutics, Inc. (South San Francisco, CA) 2033-01-04 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKesson
Colorcon
McKinsey
Dow
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.